Apogee Therapeutics’ Post

#HappeningToday at 1:30 PM ET: We are hosting a webcast to discuss the positive results from our VenoValve pivotal trial. Tune in here: https://bit.ly/3T4mlNA #CVI #VenousDisease #ChronicVenousInsufficiency

Understanding the history of FHIR is critical to grasping the fundamental who, what, when, where, why and how of the FHIR standard came to such prominence. Even as a Canadian 🇨🇦, in a globalized world it is imperative we learn about how regulations in other countries have mandated interoperability initiatives. If you're coming to the upcoming WGM (Working Group Meeting) in Dallas next week, come join me as we discuss the basic ABCs on how the history of FHIR came to be influenced by US regulations that ultimately pushed for improved patient access, better patient outcomes and greater interoperability. #HL7 #FHIR #ONC #HHS #ACA #WGM #Dallas

Visit our booth to learn about the best Mutiple Myeloma detection and monitoring!

The AF management consensus statement is an important document by the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society and the Latin American Heart Rhythm Society. This year at the #EHRA congress, the statement was updated and we were delighted to learn more about the most recent best practices surrounding catheter and surgical #ablation of AF. Interested in finding out more about our learnings from the EHRA congress and the added value of #PPG in AF management? Visit https://bit.ly/3UpDGCy

It’s 𝕆𝕔𝕥𝕠𝕓𝕖𝕣!! So that means 🎃+🍂🍁+☕️ AND T̳C̳T̳ !!! 🥳🤓🙌🏼 So many exciting things—so be sure to: Stop by our TCT hub Tuesday at 5:00 pm, as we celebrate hitting our first milestone of enrolling 1,000 patients in DEFINE GPS, a global multi-center study to assess superiority of PCI procedures guided by Co-registered iFR and interventional angiography. https://lnkd.in/gY-_GTBE

The latest #axSpA Literature highlights are now available on the #CSF including the latest study by Deodhar et al. The aim of this study was to observe the effect of IV-golumimab on fatigue in axSpA patients. They concluded that golumimab significantly improves the ASAS and ASDAS response after 16 weeks of treatment, and these improvements were sustained until the study concluded at Week 52. There were also significant improvements in BASDAI-fatigue and SF-36 vitality scores. Read the detailed slide deck and get all the latest insights for this and many more of our #axSpA, #RA, and #PsA publications this month only on the #CSF: https://lnkd.in/eqWb98iC

Transporting critically-ill patients on ECMO presents unique challenges, such as oxygenation, blood flow, and patient stability must be continuously monitored and managed during these transports. At Technimount, we understand these important challenges and offer you a safe solution for the transport of patients under ECMO. Discover how our Xtension Pro Assistant-CCT/ECMO meets the ever-evolving requirements of critical care transport here: https://lnkd.in/gEgC4XjM

#ICYMI Our latest collaborative webinar is now ready to watch on demand. Gain insights on Interprofessional High-Fidelity Cardiopulmonary Resuscitation Simulation. Learn what it is, how to implement large-scale training, and key takeaways. Presented by experts from the University of Alabama.    Request Access:    #TrainWithGaumard #HealthcareTraining #MedEd #ClinicalEducation #Trauma 

🌟New Interview 🎙️Prof Raj Makkar joins us to discuss the outcomes of repeat #TAVR with balloon-expandable valves for failed transcatheter aortic valves in the real-world national STS/ACC TVT Registry. 📽️ Watch it here 👉 https://ow.ly/lCwJ50PVHlA 📊Redo-TAVR using balloon-expandable valves successfully resolved issues from the initial TAVR procedure, resulting in low procedural complications and similar mortality and stroke rates as patients receiving TAVR for native aortic valve stenosis. 💭Is it a viable treatment choice for certain patients with failed TAVR? #CardioEd

Successful pre-TAVI IVL procedure at Military Hospital. Shockwave Medical therapy was used prior TAVI implantation due to heavily calcified and narrow femoral access. Congratulations for the innovative attitude Dr. Gábor KERECSEN and Dr. Zalán GULYÁS! Transfemoral access has the lowest morbidity and mortality rates, and reduces hospitalization time during #TAVI procedure. #IVL technology facilitates transfemoral access with high efficacy (average lumen gain 3mm) and with very low complication rates (0% perforation, embolization, thrombus). Avoiding alternative access strategies for TAVI delivery could definitely reduce procedural risk for the patients according to the latest publications. #preTAVIIVL #peripheral #IVL #Shockwave #DHSHungary #DeliveringHealthcareSolutions #healthcareinnovation